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DBackground: Vismodegib is approved for treatment of advanced basal cell carcinoma.Objective: We sought to characterize vismodegib efficacy and safety in operable basal cell carcinoma.Methods: Patients with new, operable, nodular basal cell carcinoma received vismodegib (150 mg/d)
followed by excision and Mohs micrographic surgery to ensure clear margins. Cohort 1 received
vismodegib for 12 weeks; cohort 2 received vismodegib for 12 weeks, then 24 weeks of observation
before excision; and cohort 3 received vismodegib for 8 weeks on/4 weeks off/8 weeks on.Results: In all, 24 patients enrolled in cohort 1, and 25 in cohorts 2 and 3. Complete histologic clearance
was achieved by 42%, 16%, and 44% of patients in cohorts 1, 2, and 3, respectively. Muscle spasms (76%),
alopecia (58%), and dysgeusia (50%) were the most frequent adverse events (AEs). Five (7%) patients
discontinued treatment because of an AE. AE reversibility was evaluated in cohort 2 with 24 weeks of
observation after treatment discontinuation.Limitations: Nonrandomized, small cohort sizes, and short observation durations for some patients are
limitations.Conclusion: Primary efficacy end points were not met (predefined complete histologic clearance rate:
[50% in cohorts 1 and 3;[30% in cohort 2). Safety was comparable when dosed continuously versus
intermittently. Posttreatment reversibility of vismodegib-related AEs was demonstrated. ( J Am Acad
Dermatol 2015;73:99-105.)
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100 Sofen et alAberrant activation of the hedgehog pathway is
important in basal cell carcinoma (BCC) pathogen-
esis.1 Vismodegib (Erivedge, Genentech, South San
Francisco, CA), a hedgehog pathway inhibitor,2,3 was
approved by the US Food and Drug Administration
(FDA) in 2012 and the EuropeanMedicines Agency in
2013 for treatment of adults with locally advanced orCAPSULE SUMMARY
d Vismodegib has demonstrated activity in
advanced basal cell carcinoma. This
study evaluated activity in operable
basal cell carcinoma.
d Although complete histologic clearance
was achieved in up to 44% and complete
clinical response in 50% of patients
receiving short course vismodegib, the
prespecified level of efficacy was not
achieved.
d This study demonstrated that
vismodegib-related adverse events were
reversible on treatment discontinuation.metastatic BCC.
This study evaluated activ-
ity of vismodegib in patients
with smaller operable BCC
by measuring the rate and
durability of complete histo-
logic clearance (CHC) of le-
sions. Safety with different
durations of treatment and
follow-up, including resolu-
tion of adverse events (AEs),
was also assessed.
METHODS
Study design
This nonrandomized, 3-
cohort, open-label, phase II
study was conducted at 9
sites in the United States
(ClinicalTrials.gov identifier: NCT01201915). A Mohs
experienced surgeon acted as principal investigator
or subinvestigator.
Cohort 1 evaluated CHC rate after 12 weeks of
treatment. Cohort 2 evaluated durability of CHC after
a 12-week course and a 24-week observation period.
To assess whether intermittent dosing improved
tolerability, a protocol amendment added cohort 3
evaluating two 8-week treatment periods separated
by a 4-week drug holiday (Fig 1).
The study was conducted per FDA regulations,
International Conference on Harmonization E6
Guideline for Good Clinical Practice, and applicable
local, state, and federal laws. Protocol approved by
institutional review boards where applicable.
Patients gave written informed consent.
Patients
Patients were 21 years of age or older, with new,
operable, biopsy-confirmed, nodular BCC and
willing to delay excision.One target lesion per patient
located a sufficient distance from nontarget lesions
avoided ambiguity in margin assessment. Enrollment
in cohort 1 was limited to patients with lesions on the
scalp/head/neck (0.5-2.0 cm) or cape area of the
upper aspect of the trunk (1.0-3.0 cm). In cohorts 2
and 3, eligibility included lesions on the scalp/head/
neck (0.5-2.0 cm) and on the greater trunk/limbs (1.0-
3.0 cm). Patients had adequate baseline hematologicfunction and hepatic function. Cases with histologic
subtypes other than nodular BCC, Gorlin syndrome,
prior treatmentwith anyhedgehogpathway inhibitor,
and pregnancy or lactation were excluded.
Interventions
Patients received vismodegib at 150 mg/d. Dosereduction was not permitted.
All target sites, even if clini-
cally clear at the time of
surgery, were excised by
standard means, followed
by Mohs micrographic sur-
gery to obtain clear margins.
In cohorts 1 and 3, all
patients underwent excision
and Mohs micrographic sur-
gery within 2 weeks of dis-
continuing treatment. In
cohort 2, excised lesions
and margins were evaluated
with Mohs micrographic sur-
gery at the end of a 24-week
observation period.
Study assessments
The primary objective was to evaluate rate of CHC
of target lesions at end-of-treatment period (cohorts
1 and 3) or after 24 weeks of observation (cohort 2).
CHCwas defined as absence of BCC in excised target
site by histology.
After excision, specimens were sent to a central
laboratory (Genentech Pathology, South San
Francisco, CA) for histologic evaluation by an inde-
pendent pathologist and examined for evidence of
residual tumor (breadloafed). Secondary efficacy
end point was time from vismodegib initiation to
investigator-assessed complete clinical clearance. All
tumor assessments were performed every 4 weeks.
AEs were recorded at each visit. All patients were
followed up for safety until 30 days after Mohs
micrographic surgery or last dose of study drug if
Mohs micrographic surgery did not occur.
Statistical analysis
Evaluable patients received 1 or more doses of
vismodegib and were included as nonresponders if
they discontinued before evaluation for CHC or
durable CHC. Study hypotheses were that the CHC
rate would be more than 50% in cohorts 1 and 3, and
the durable CHC rate would be more than 30% in
cohort 2 (1-sided a = 0.10).
Safety analyses included summaries of AEs,
serious AEs (SAEs), treatment-emergent AEs, and
AEs leading to discontinuation, graded according to
Abbreviations used:
AE: adverse event
BCC: basal cell carcinoma
CHC: complete histologic clearance
FDA: Food and Drug Administration
SAE: serious adverse event
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RESULTS
A total of 74 patients enrolled between October 5,
2010, and November 29, 2012: 24 in cohort 1, and 25
each in cohorts 2 and 3 (Fig 2). In all, 49 patients (66%)
completed the study, and 25 (34%) discontinued early
(patient decision to withdraw [n = 11; 15%], AEs [n = 4;Cohort 1 (n = 24): Assessment of CHC
Lesion sites: Scalp/head/neck and cape area 
12 weeks Tx 30 d F/U 
PK sample (Week 9)
Mohs surgery*
D1 
12 weeks Tx
PK sample (Week 9)D1
24 week
8 weeks Tx 30 d F/U 
PK sample (Week 
Mohs surgery‡
D1 
4 weeks
no Tx 8 weeks Tx
Cohort 2 (n = 25): Assessment of CHC dura
Lesion sites: Scalp/head/neck and trunk/limbs
Cohort 3 (n = 25): Assessment of CHC 
Lesion sites: Scalp/head/neck and trunk/limbs
Fig 1. Treatment (Tx) interventions and assessme
vismodegib Tx prematurely, the target lesion wa
Mohs evaluation of margins was performed be
investigator chose. yPatients who discontinued vi
of Tx did not enter the 24-week observation p
micrographic surgery between weeks 13 and 15; p
and 12 entered the observation period, and un
surgery at week 37. zPatients who discontinued
Mohs evaluation at week 20, or earlier if the inv
clearance; D1, day 1; F/U, follow-up; PK, pharma5%], lost to follow-up [n = 4; 5%], physician decision to
withdraw [n = 3; 4%], and target lesionprogression [n =
3; 4%, all from cohort 2]). Patient demographics and
baseline disease characteristics are listed in Table I.
Efficacy
The predefined CHC rate of more than 50% was
not met in either cohort 1 (10 of 24 patients, or 42%
[P = .85]) or cohort 3 (11 of 25 patients, or 44%
[P = .79]). In cohort 2, 4 of 25 (16%) patients achieved
durable CHC lasting 24 weeks or more beyond the
end of the 12-week treatment period (P = .97),
which did not meet predefined threshold of more
than 30% (Table II). Examples of 2 patients are
presented in Fig 3.
Investigator-assessed complete clinical clearance
was observed in 37 patients (50%), including 1030 d 
F/U 
Mohs surgery†
s observation
bility
 
 
nts by cohort. *In patients who discontinued
s removed with conventional excision and
tween weeks 13 and 15, or earlier if the
smodegib before the completion of 8 weeks
eriod, but underwent excision and Mohs
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derwent excision and Mohs micrographic
early underwent target lesion excision and
estigator chose. CHC, Complete histologic
cokinetic.
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Fig 2. Patient disposition.
Table I. Demographic data and baseline characteristics
Demographic or baseline characteristic
Cohort 1
n = 24
Cohort 2
n = 25
Cohort 3
n = 25
All patients
N = 74
Age, y
Median (range) 59.0 (43-81) 65.0 (40-86) 61.0 (47-89) 61.5 (40-89)
Sex, n (%)
Male 19 (79) 22 (88) 17 (68) 58 (78)
Female 5 (21) 3 (12) 8 (32) 16 (22)
Race, n (%)
White 23 (96) 25 (100) 25 (100) 73 (99)
Native American 1 (4) 0 0 1 (1)
Longest diameter of nodular BCC, cm
Median (range) 1.2 (1-3) 1.5 (1-2) 1.2 (1-3) 1.3 (1-3)
Concomitant medications, n (%)
Any 22 (92) 25 (100) 24 (96) 71 (96)
BCC, Basal cell carcinoma.
Table II. Complete histologic clearance rate with
vismodegib in cohorts 1, 2, and 3
BCC histopathology
Cohort 1
n = 24
Cohort 2
n = 25*
Cohort 3
n = 25
Patients achieving CHC, n 10 4 11
CHC rate, % 42 16 44
95% CI 22.1-63.4 4.5-36.1 24.4-65.1
P value .85 .97 .79
Hypotheses were formally tested using a 1-sided exact binomial
test at the 1-sided a = 0.10 level. The 95% CI for response rates
was calculated using the Clopper-Pearson exact method.
BCC, Basal cell carcinoma; CHC, complete histologic clearance; CI,
confidence interval.
*Four patients did not have evaluable data for durable CHC and
were included in the analysis as nonresponders.
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in cohort 3. Median time to complete clinical
clearance (in those who achieved it) was 59.5 days
(95% confidence interval 28-80) in cohort 1, 84 days
(95% confidence interval 27-120) in cohort 2, and
60 days (95% confidence interval 55-86) in cohort 3
(Table III).
Safety
In all, 73 patients (99%) developed 1 or more
treatment-emergent AEs (Table IV, available at
http://www.jaad.org). Most frequent AEs ($30% of
patients) included muscle spasms (76%), alopecia
(58%), dysgeusia (50%), and ageusia (30%). Grade-3
AEs occurred in 14 patients (19%), with muscle
Fig 3. Case examples of patients treated with vismodegib. A, Complete histologic clearance
after excision (patient 23036; white male, 59 years of age). B, Small focus of residual disease on
histologic analysis after excision (patient 23056; white male, 57 years of age). BCC, Basal cell
carcinoma; CR, complete response; PR, partial response.
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or deaths were reported. SAEs were reported in 6
patients (8%) including atrial fibrillation,hemorrhoidal hemorrhage, small intestinal hemor-
rhage, hepatitis, bladder cancer, liposarcoma, and
ischemic stroke. Most SAEs were considered
Table III. Investigator-assessed complete clinical
clearance in all cohorts
n
Investigator-
assessed
CCC, n (%)
Median (95% CI)
time to investigator-
assessed CCC, d
Cohort 1 24 10 (42) 59.5 (28-80)
Cohort 2 25 9 (36) 84 (27-120)
Cohort 3 25 18 (72) 60 (55-86)
Total 74 37 (50)
Kaplan-Meier method used to estimate median time to CCC; 95%
CIs computed using Brookmeyer-Crowley method.
CCC, Complete clinical clearance; CI, confidence interval.
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patient experienced an SAE of hepatitis and hemor-
rhoidal hemorrhage. The event of hepatitis was
considered related and resolved within 2 months of
study drug discontinuation.
Treatment was discontinued because of AEs in 2
patients from cohort 1 (8%), 1 from cohort 2 (4%),
and 1 (4%) from cohort 3. Dysgeusia was the most
frequent AE leading to discontinuation (n = 3; 4%),
followed by muscle spasm (n = 2; 3%), and alopecia
(n = 2; 3%).
The incidence of muscle spasms evenly distributed
across cohorts (cohort 1, 79%; cohort 2, 76%; cohort 3,
72%),with amedian time toonset of34, 26, and27days
andmedian duration of 61, 73, and 115 days in cohorts
1, 2, and 3, respectively (Table V, available at http://
www.jaad.org). A lower incidence of alopecia was
observed in cohort 1 (33%) compared with cohorts 2
(68%) and 3 (72%). Median time to onset was 115, 75,
and 68 days in cohorts 1, 2, and 3, respectively, and
occurred after treatment discontinuation in 7 of 8
patients in cohort 1 and 9 of 17 patients in cohort 2.
Median durationwas 64, 89, and 134 days in cohorts 1,
2, and 3, respectively (Table V). The incidence of
dysgeusiawas38%, 52%,and60% incohorts 1, 2, and3,
respectively.Median time to onset of dysgeusiawas 24,
41, and 26 days in cohorts 1, 2, and 3, respectively.
Median durationwas 63 and82days in cohorts 1 and 2,
respectively, and could not be estimated in cohort 3
(TableV).Median time to onsetwas 21, 15, and 15days
and median duration was 108, 134, and 124 days in
cohorts 1, 2, and 3, respectively (Table V).
Importantly, the longer observation period in
cohort 2 enabled exploration of reversibility of
common AEs (Table V). Muscle spasm: 16 of 19
patients achieved full resolution within 6 weeks of
end of treatment, and the remaining three grade-1
AEs resolved within 12 weeks of end of treatment.
Among the 17 patients with alopecia, 4 patients had
grade 1 alopecia ongoing at study end. For dysgeu-
sia, 11 of 13 patients achieved resolution within 12
weeks of end of treatment, whereas the remaining 2patients had ongoing grade-1 dysgeusia at study end
(after 24 weeks’ follow-up). Of 5 patients reporting
ageusia in cohort 2 (all grade 1), all events fully
resolved within 12 weeks of end of treatment.
DISCUSSION
This study did not achieve its predefined primary
end points of independent pathologist-determined
CHC, either in cohort 1 after 12 weeks of continuous
vismodegib treatment, or in cohort 3 after 16 weeks of
intermittent vismodegib treatment, or durable CHC in
cohort 2 after 24 weeks of follow-up. However, the
treatment regimens in this study were somewhat well
tolerated as noted by the low discontinuation rate (4
patients [5%] discontinued treatment because of AEs).
To date, more than 4000 patients with BCC have
received treatmentwith vismodegib, and its AE profile
has shown general consistency across populations
and indications,3-5 although individual incidences
may vary with treatment duration.6 In our study, the
safety profile of vismodegib (150 mg daily) was
comparable when dosed as a short-term continuous
regimen or intermittently, and was generally consis-
tent with clinical experience.7
Our data generally showed reversibility of muscle
spasms, dysgeusia, and ageusia in the 6 to 12 weeks
after drug discontinuation, and reversibility of
delayed-onset alopecia in most patients during the
24-week follow-up period in cohort 2. Several differ-
ences in AEs were noted among cohorts, including
incidences and times to onset. It is difficult to
concludewhether these observations could be related
to differences in total treatment exposures and follow-
up periods, or a combination of factors, because of
the small number of patients in each cohort.
Moreover, patient assignment to cohorts was not
randomized, limiting comparisons across cohorts.
Conclusions
The efficacy and safety of vismodegib continues
to be investigated. Further studies are needed to
evaluate any cumulative toxicity with extended
treatment times and to explore strategies to amelio-
rate common AEs.6 The prespecified level of efficacy
was not achieved in patients with operable BCC.
However, this study showed good reversibility of the
most common AEs (muscle spasm, alopecia, dys-
geusia, and ageusia) associated with vismodegib.
The authors thank David Gibson, PhD, CMPP, Jennifer
M. Kulak, PhD, and Geraldine Hosking of ApotheCom
(Yardley, PA) for medical editorial assistance.
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Table IV. Treatment-emergent adverse events reported in 5% or more of patients overall
AE* by MedDRA-preferred term, n (%)
Cohort 1
n = 24
Cohort 2
n = 25
Cohort 3
n = 25
All patients
N = 74
Any AE 24 (100) 25 (100) 24 (96) 73 (99)
Muscle spasm 19 (79) 19 (76) 18 (72) 56 (76)
Alopecia 8 (33) 17 (68) 18 (72) 43 (58)
Dysgeusia 9 (38) 13 (52) 15 (60) 37 (50)
Ageusia 10 (42) 5 (20) 7 (28) 22 (30)
Fatigue 5 (21) 3 (12) 7 (28) 15 (20)
Nausea 5 (21) 2 (8) 6 (24) 13 (18)
Decreased appetite 3 (13) 1 (4) 4 (16) 8 (11)
Madarosis 3 (13) 2 (8) 3 (12) 8 (11)
Constipation 1 (4) 3 (12) 3 (12) 7 (9)
Diarrhea 2 (8) 1 (4) 3 (12) 6 (8)
Dyspepsia 2 (8) 1 (4) 2 (8) 5 (7)
AE, Adverse event; MedDRA, Medical Dictionary for Regulatory Activities.
*AEs occurring during treatment or follow-up phase. AEs were summarized by MedDRA (Version 16.0) system organ class and preferred
term.
Table V. Median time to onset of selected adverse events, and median time to adverse event resolution, by
cohort
AE Cohort n
Median (95% CI) time to AE
onset, d
Median (95% CI) AE duration/
time to resolution, d
No. (%) of patients with AE
ongoing at study treatment end
Muscle
spasm
1 19 34 (15-43) 61 (15-43) 1 (5)
2 19 26 (21-39) 73 (63-85) 0 (0)
3 18 27 (14-50) 114.5 (39-152) 3 (17)
Alopecia 1 8 114.5 (58-135) 64 (13-64) 5 (62.5)
2 17 75 (60-95) 89 (59-165) 4 (24)
3 18 67.5 (57-74) 134 (29-140) 16 (89)
Dysgeusia 1 9 24 (8-63) 63 (3-107) 2 (22)
2 13 41 (19-54) 82 (59-123) 2 (15)
3 15 26 (12-32) NE (145-NE)* 11 (73)
Ageusia 1 10 20.5 (8-38) 108 (51-134) 3 (24)
2 5 15 (6-35) 134 (76-150) 0 (0)
3 7 15 (11-27) 124 (42-173) 4y (57)
Cohort 1 received vismodegib for 12 weeks; cohort 2 received vismodegib for 12 weeks, then 24 weeks of observation before excision; and
cohort 3 received vismodegib for 8 weeks on/4 weeks off/8 weeks on.
AE, Adverse event; CI, confidence interval; NE, not estimable.
*Range, 36-181 days.
yOne patient with ageusia in cohort 3 discontinued the study before the 4-wk treatment break.
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